UNSPSC 51182202: Methylergometrine or methylergonovine

This classification denotes a cns stimulant with the molecular formula C20H25N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W53L6FE61V, chemically known as 9,10-didehydro-n-(alpha-(hydroxymethyl)propyl)-6-methyl-ergoline-8-beta-carboxamide but generally known as methylergometrine, which bears US NIH Compound Identifier 8226. European Medicines Agency schedules Methylergometrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08868MIG.

UNSPSC 51182202 Methylergometrine or methylergonovine, a Commodity code, covers pharmaceutical products that state and local government healthcare facilities procure through cooperative purchasing vehicles and direct supplier contracts. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is actively soliciting manufacturers and distributors of generic multi-source pharmaceuticals and over-the-counter products that serve state and local health systems. The scope of work encompasses supply of pharmaceutical products with specific National Drug Codes (NDC), complete product data including SKUs, UPCs, generic descriptions, strength, dosage form, trade names, and packaging configurations, and fulfillment through authorized wholesalers with established chargeback systems. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain inventory available by May 15, 2026, and offer flexible pricing models including flat-price, net-price formats (NF30, NF60, NF90), or WAC-minus structures. The RFP emphasizes price competitiveness (weighted at 75 percent in evaluation) alongside administrative fee compliance, EDI capability, and fixed pricing for the contract term. Issuing bodies include state health agencies and local government facilities participating in cooperative purchasing consortia; MMCAP itself coordinates procurement across multiple member states including Minnesota and Oregon.

The geographic scope spans the MMCAP member states, with Minnesota as the administering jurisdiction and Oregon explicitly identified as a participating state. The Minnesota Multistate Cooperative Purchasing Alliance RFP for Generic Multi Source Pharmaceuticals and OTC Products (Solicitation S1070000015802, due March 26, 2026) represents the most recent opportunity under this code. The RFP requires responses through the ePro procurement system with pricing and product information in CSV format, establishes a two-year contract term effective July 1, 2026 (with optional extensions at MMCAP's discretion), and mandates comprehensive insurance including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability per occurrence. The structure reserves MMCAP's right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs, with performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials.